Background:Current amblyopia screening methods are not cost effective.Aim:To evaluate the diagnostic capability of a modified Brückner test (MBT) for amblyopiogenic risk factors.Materials and Methods:We applied the MBT using the streak retinoscope to identify anisometropia and strabismus by noting an inter-ocular difference in movement and glow, from children who failed 6/9 Snellen on community vision screening, followed by comprehensive eye examination.Statisitics:Data were analyzed by 2 × 2 tables for diagnostic test parameters (95% CI).Results:From 7998 children vision-screened, 392 failed 6/9 VA and were referred. Since 34 failed to reach the centers, and 15 were excluded due to poor/ no glow, data from 343 was analyzed. The prevalence of anisometropia of 0.5D was 17%, of 1D was 11% and of strabismus 5%. For the MBT the accuracy was ≥ 90% (95%CI 89% to 97%) over the three outcomes. The sensitivity, specificity, NPV and +LR for anisometropia of 0.5D were: 0.57 (0.48, 0.64), 0.97 (0.95, 0.98), 0.92 (0.90, 0.93) and 18 (9.7, 35); for 1D: 0.74(0.60, 0.82), 0.95 (0.94, 0.97), 0.97 (0.95, 0.98) and 16 (9.3, 28); and for strabismus: 0.5 (0.32, 0.66), 0.98 (0.97, 0.98), 0.97 (0.96, 0.98) and 20 (9.1, 42).Conclusion:Our data suggests that the MBT is highly accurate and useful for ruling in anisometropia and strabismus in children who fail 6/9 Snellen. The MBT needs further validation, both by different care givers and on differing populations. It offers an affordable, portable, and clinically useful tool to detect anisometropia and strabismus. We suggest that performing an MBT prior to uniocular retinosocpy should be a routine practice.
Le but de ce travail est d'étudier le profil épidémiologique, clinique, thérapeutique et évolutif des manifestations oculaires au cours de la Maladie de Behçet. C'est une étude rétrospective descriptive étalée sur une période d'un an et demi entre janvier 2015 et juin 2016 analysant les dossiers de 121 patients suivis à la consultation spécialisée de la maladie de Behçet. La moyenne d'âge était de 35 ans, 63,6% des patients étaient de sexe masculin, l'atteinte oculaire était inaugurale dans 24% des cas. Les patients présentaient une uvéite antérieure (7,4%), une uvéite postérieure (15,7%), une vascularite (19%), des synéchies irido-cristalliniennes (17,5%), un œdème maculaire (7,4%), une atrophie optique (4,1%), un œdème papillaire (2,5%) et une ischémie rétinienne périphérique (1,7%). Dans notre série 41,3% des patients étaient sous colchicine, 23,1% sous corticoïdes par voie orale, 9% sous corticoïdes par voie intraveineuse, 4,9% sous corticoïdes topiques, 8,2% sous immunosuppresseurs et 5,8% sous anti-vitamine K. Sur un recul moyen d'une année, 40% des patients avaient une acuité visuelle stable sous traitement, 23% ont présenté une baisse significative de l'acuité visuelle dont 5% des cas de cécité absolue. Une prise en charge thérapeutique correcte permet de juguler rapidement la poussée inflammatoire et de réduire la fréquence et la gravité des récidives ce qui se traduit par une amélioration du pronostic visuel de nos patients par rapport à des séries antérieures.
Optic disc drusen (ODD) are abnormal collections of protein and calcium that accumulate within the optic nerve. We report a case of a 17-year-old girl who presented to the Department of Ophthalmology at the
Extraocular muscle biopsy is a technique used for the histological diagnosis of several orbital diseases; it could bring valuable assistance to the diagnostic process. The purpose of this article is to review the indications, surgical technique, and complications of this biopsy.Extraocular muscle biopsy is frequently used in tumoral pathology, however, in inflammatory diseases, it is only used when facing a poor reaction to the treatment or in case of chronicity. The surgical procedure must be precise and least traumatic, in order to avoid intra-and post-operative complications, but also to preserve the integrity and function of the muscle. This procedure remains non-standardized and not devoid of complications, hence the need for a careful evaluation of the benefit/risk ratio before considering it.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.